As part of your program, youll receive a personalized diet and exercise plan
Overview of the Phase 2 NEJM Trial Design and Participants The phase 2 trial was a randomised, double-blind, placebo-controlled, dose-ranging study enrolling 338 adults with obesity or overweight without type 2 diabetes, assessing retatrutide doses of 1 mg, 4 mg, 8 mg, and 12 mg over 48 weeks
Questions to Ask Your Healthcare Team Before starting Retatrutide after bariatric surgery, consider asking your providers these questions
Obesity is a major risk factor for many chronic conditions like type 2 diabetes and cardiovascular diseases
Silvestro says
Individuals with diabetes are at particularly high risk of NAFLD, theorized to be due to excess energy driving insulin resistance seen in diabetes resulting in increased uptake of free fatty acids in the liver